Distribution of Disease-Causing Mutations through Different Protein Domains in Patients with Severe Combined Immunodeficiency
Archives of Medical Laboratory Sciences,
Vol. 5 No. 4 (2019),
23 September 2019
,
Page 1-7
https://doi.org/10.22037/amls.v5i4.30891
Abstract
Background and Aim: Severe combined immunodeficiency (SCID) has been described as the most severe form of primary immunodeficiency disorders (PID). The disease can be caused by mutations in more than 20 different genes with prevalence of 1 in 50000 to 100000 live births. In the present study, we described the protein domain position of variants in 14 main genes in patients with SCID. We also aimed to investigate the correlation between the variant distribution of protein domains and its pathogenicity and clinical outcome of the variant. Materials and Methods: Molecular genetic analysis including Sanger sequencing, targeted gene panel and whole exome sequencing were performed on 50 patients with SCID. Moreover, protein domains characteristics were extracted from different databases such as Uniprot and PDB and the reported mutations were obtained from HGMD and ENSEMBL databases. Results: Our results showed that the mortality rate had a significant correlation with severity of clinical manifestations in the patients (p-value=0.000). There was also a significant relationship between the protein type and mutation severity (p-value=0.001) and severity of clinical manifestations (p-value=0.025). However, there was no significant relationship between the mortality rate and occurrence of mutations in different domains of proteins (p-value=0.304) and the severity of mutations (p-value= 0.586). Conclusion: In severe genetic diseases such as SCID, mutations in related genes have affected the structure of the protein enough to cause severe symptoms. However, there are differences in the pathogenicity of the mutations based on their location on the protein domains. In order to determine these variations and predict the outcome of mutations, it is necessary to use in silico and laboratory methods along with statistical and data mining tools to track these minor differences.
- Primary Immunodeficiency
- Severe Combined Immunodeficiency (SCID)
- Protein Domain
- Variant Interpretation
How to Cite
References
Erman B, Bilic I, Hirschmugl T, Salzer E, Boztug H, Sanal Ö, et al. Investigation of genetic defects in severe combined immunodeficiency patients from Turkey by targeted sequencing. Scand J Immunol. 2017;85(3):227-34.
Puck JM, Group SNSW. Population-based newborn screening for severe combined immunodeficiency: steps toward implementation. J Allergy Clin Immunol. 2007;120(4):760-8.
Parvaneh N, Casanova J-L, Notarangelo LD, Conley ME. Primary immunodeficiencies: a rapidly evolving story. J Allergy Clin Immunol. 2013;131(2):314-23.
Sponzilli I, Notarangelo LD. Severe Combined Immunodeficiency (SCID): from molecular basisto clinical management. Acta Biomed. 2011;82(1):5-13.
Fischer A, Le Deist F, Hacein-Bey-Abina S, Andre-Schmutz I, Basile Gde S, de Villartay JP, et al. Severe combined immunodeficiency. A model disease for molecular immunology and therapy. Immunol Rev. 2005;203:98-109.
McGhee SA, Stiehm ER, McCabe ER. Potential costs and benefits of newborn screening for severe combined immunodeficiency. J Pediatr. 2005;147(5):603-8.
Kuo CY, Kohn DB. Gene therapy for the treatment of primary immune deficiencies. Curr Allergy Asthma Rep. 2016;16(5):39.
Kumrah R, Vignesh P, Patra P, Singh A, Anjani G, Saini P, et al. Genetics of severe combined immunodeficiency. Genes & Diseases. 2020;7(1):52-61.
Fazlollahi M, Pourpak Z, Hamidieh A, Movahedi M, Houshmand M, Badalzadeh M, et al. Clinical, Laboratory and Molecular Findings of 63 Patients with Severe Combined Immunodeficiency. A Decade s Experience. J Investig Allergol Clin Immunol. 2017;27(5):299-304.
Kumar P, Henikoff S, Ng PC. Predicting the effects of coding non-synonymous variants on protein function using the SIFT algorithm. Nature protocols. 2009;4(7):1073.
Adzhubei I, Jordan DM, Sunyaev SR. Predicting functional effect of human missense mutations using PolyPhen‐2. Current protocols in human genetics. 2013;76(1):7.20. 1-7.. 41.
Mather C, Salipante S, Scroggins S, Turner E, Shirts B, Wu D, et al., editors. Performance characteristics of Combined Annotation-Dependent Depletion (CADD) scores in clinical next-generation sequencing cancer panels. JOURNAL OF MOLECULAR DIAGNOSTICS; 2014: ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA.
Liu J, Rost B. Sequence-based prediction of protein domains. Nucleic acids research. 2004;32(12):3522-30.
Finn RD, Attwood TK, Babbitt PC, Bateman A, Bork P, Bridge AJ, et al. InterPro in 2017—beyond protein family and domain annotations. Nucleic acids research. 2017;45(D1):D190-D9.
Shahbazi Z, Yazdani R, Shahkarami S, Shahbazi S, Hamid M, Sadeghi-Shabestari M, et al. Genetic mutations and immunological features of severe combined immunodeficiency patients in Iran. Immunology letters. 2019;216:70-8.
Aghamohammadi A, Abolhassani H, Kutukculer N, Wassilak SG, Pallansch MA, Kluglein S, et al. Patients with primary immunodeficiencies are a reservoir of poliovirus and a risk to polio eradication. Frontiers in immunology. 2017;8:685.
Shahbazi Z, Parvaneh N, Shahbazi S, Rahimi H, Hamid M, Shahbazi D, et al. Graft versus host disease and microchimerism in a JAK3 deficient patient. Allergy, Asthma & Clinical Immunology. 2019;15(1):1-9.
Fang M, Abolhassani H, Lim CK, Zhang J, Hammarström L. Next generation sequencing data analysis in primary immunodeficiency disorders–future directions. Journal of clinical immunology. 2016;36(1):68-75.
Cossu F. Genetics of SCID. Ital J Pediatr. 2010;36(1):76.
Puck JM, Pepper AE, Henthorn PS, Candotti F, Isakov J, Whitwam T, et al. Mutation analysis of IL2RG in human X-linked severe combined immunodeficiency. Blood. 1997;89(6):1968-77.
Tasher D, Dalal I. The genetic basis of severe combined immunodeficiency and its variants. Appl Clin Genet. 2012;5:67.
Vihinen M, Villa A, Mella P, Schumacher RF, Savoldi G, O'Shea JJ, et al. Molecular modeling of the Jak3 kinase domains and structural basis for severe combined immunodeficiency. Clin Immunol. 2000;96(2):108-18.
- Abstract Viewed: 86 times
- pdf Downloaded: 52 times